Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Projects We Work On
Private Financing
Overview
If you're the founder or CFO of a science-based startup, you need to understand your financing options. You’re looking for a law firm that can introduce you to venture capitalists and other funding sources, and at the same time, you want legal counsel that understands your company’s potential in order to strike a deal that acknowledges the value you’re creating and protects your interests.
We work with you to structure financing that aligns your interests with those of investors, while fairly balancing control and decision-making.
Experience
At Faber, we’ve represented 2,000+ clients in life science, healthcare IT, medical devices and engineering technology. We often act as corporate counsel and provide legal guidance to management and boards of directors alike on the full range of private financing options.
We have strong relationships with the investor groups that focus on these verticals and have advised many of them on their own transactions.
Based on your circumstances, we’ll advise you on the optimal source of financing, including:
- Founders’ agreements
- Angel financing
- Venture capital
- Foundation grants
- Government investment programs
- Venture debt
- Equipment financing and capital leasing
- Conventional bank financing
- Royalty financing
- Shareholder agreements
- Equity compensation
We have been actively involved in preparing model documents published by the National Venture Capital Association. But we also recognize that successful deals are about more than contract terms. Faber’s sector focus prepares us to understand your opportunities and challenges.
Related Transactions
Claris Biotherapeutics, Inc.
Series A-3 Preferred Stock FinancingClaris Bio closes latest venture round to bring total financing to roughly $60 million, accelerating its late-stage clinical development of a novel therapeutic agent for neurotrophic keratopathy. Investors include Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, and Janus Henderson Investors
Press Release
GV (Google Ventures) + ARCH Ventures
Chroma Medicine Series B FinancingRepresentation of GV, as lead, ARCH Venture Partners and DCVC in Chroma Medicine’s $135M Series B Financing
Press Release
NextPoint Therapeutics, Inc.
Series B Financing - $80 millionNextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Existing investors that took part in the financing include MPM Capital Management and Dana-Farber Cancer Institute
Website
6 Dimensions Capital
VC InvestmentsEquity investments in multiple portfolio companies, including Hibercell
Website
Epalex Corporation
Series A-3 FinancingSeries A-3 preferred equity financing to continue advancing Epalex’s two clinical-stage development programs
Website
Vizgen, Inc.
Series C FinancingVizgen raises Series C equity funding led by Blue Water Life Science Advisors, LLC, ARCH Venture Fund X, L.P. and other existing investors
Press Release
Vernal Biosciences, Inc.
Series A FinancingVernal Biosciences raises $21M Series A equity funding led by Dynamk Life Sciences Fund, L.P., Charles River Laboratories, Inc. and Ampersand 2020 Limited Partnership
Press Release
Artax Biopharma, Inc. + Advent Life Sciences Fund II LP
Series B Financing (Series B4)Artax Biopharma raises Series B-4 round of equity funding led by Advent Life Sciences Fund II LP, Advent Life Sciences LLP, Columbus Life Science Fund II, FCR, Hiyuli Ventures Limited, Belinda A. Termeer, and other existing investors, plus new investors including Sound Bioventures Fund I AB and and Eli Lilly
Press Release
Dianthus Therapeutics OpCo, Inc.
Series A FinancingDianthus raises $100 million Series A financing led by 5AM Ventures, Fidelity Management & Research Company, Avidity Partners, Venrock, Fairmount Funds, Tellus BioVentures and other investors
Press Release
Summation Bio, Inc.
Series A FinancingSummation Bio raises Series A equity funding led by RA Capital Healthcare Fund, L.P., RA Capital NEXUS Fund, L.P., RA Capital NEXUS Fund III, L.P., Blackwell Partners LLC and other existing investors
Aliada Therapeutics, Inc.
Series Seed-1 FinancingCounsel to Aliada in completing its Series Seed financing, with investment from Johnson & Johnson Innovation, RA Capital, OrbiMed and Sanofi Ventures
Website
Vizgen, Inc.
Series B FinancingVizgen raises Series B equity funding from Northpond Ventures LP, ARCH Venture Fund X, L.P., Novalis LifeSciences LLC, Tao Capital Management, Pura Vida Investments and other current investors
Press Release
GV (Google Ventures) + Hyperfine Research
Series D FinancingFaber has assisted GV in Hyperfine Research’s $90M Series D Financing
Press Release
5AM Venture Management LLC + Pear Therapeutics, Inc.
Series D FinancingSeries D Financing of Pear Therapeutics, Inc.
Press Release
RA Capital Management, LLC
Series B FinancingFaber has assisted RA Capital as the co-lead in a $110 million Series B Financing in Vor Biopharma
Press Release
Adrienne Lazure
Senior Administrative Assistant and Associate Corporate Paralegal
